The trial included over 13,000 people across 30 countries and ran for more than 4.5 years, making it the largest and longest study on tirzepatide so far, the company said ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Health and Human Services Secretary Robert F. Kennedy Jr. and agency leaders have attributed a panoply of chronic diseases ...

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...

Several new weight loss drugs are undergoing trials in the UK. These drugs will work similarly to those already available but ...

Over a fifth of people in the UK have tried to access a weight loss drug in the last year, according to a recent poll.Authors Liz Breen Professor ...

Demand for drugs, including weight-loss injections, is sending people to dangerous places to get their medicine. But spotting ...